Zovilda M 500mg/50mg Tablet is a fixed-dose combination medication containing Metformin 500mg and Vildagliptin 50mg, indicated for the management of type 2 diabetes mellitus. Metformin, a biguanide class agent, primarily acts by decreasing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake, thereby aiding in glycemic control. Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases the levels of incretin hormones, which stimulate insulin release and suppress glucagon secretion in a glucose-dependent manner, contributing to improved postprandial and fasting blood glucose levels. The combination therapy is particularly beneficial for patients inadequately controlled on metformin monotherapy or those requiring dual therapy to achieve optimal glycemic targets. Zovilda M should be administered orally, typically twice daily with meals to minimize gastrointestinal side effects. It is contraindicated in patients with severe renal impairment, metabolic acidosis, or hypersensitivity to its components. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, while hypoglycemia risk remains low due to the glucose-dependent action of vildagliptin. Regular monitoring of renal function and glycemic parameters is recommended to ensure safety and efficacy during treatment.